Nykode Therapeutics : presentation from ABGSC Seminar on Autoimmunity, Transplantation & Inflammation

ABGSC Seminar -

Autoimmunity,

Transplantation &

Inflammation

June 11, 2024

Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

2

Global leader in antigen presenting cell (APC)-targeted immunotherapy technology

NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$500M1)

Differentiated immunotherapies targeting antigens to Antigen-Presenting Cell (APC) to direct tailor-made immune responses with focus on oncology and autoimmune diseases

Broad pipeline de-risked through strong durability and survival data

• Lead asset VB10.16 in potential registrational trial in r/m cervical cancer. Expanding into additional indications with high unmet need including r/m Head and Neck

Strategic partnerships with top tier US biopharma companies2

♦ Personalized cancer vaccine in partnership with Genentech

♦ Multiprogram (oncology and infectious diseases) collaboration with Regeneron

Autoimmune disease constitute a potential new therapeutic vertical in high-unmet need indications (e.g., MS, T1D)

Well-capitalized with a cash position of $147.3m at March 31, 2024

1. Based on closing share price of NOK 16.08 on June 3, 2024 and USD/NOK exchange rate of 10.50.
2. Note: Genentech has an exclusive license to VB10.NEO. Collaboration and license to 5 programs with Regeneron. Collaboration and license with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine. Roche supplies atezolizumab. Merck (MSD) supplies pembrolizumab

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

3

Broad pipeline targeting early to late-stage cancer treatment

									Upcoming
	Asset	Indication	Rights		Preclinical	Phase 1	Phase 2	Phase 3	Catalyst
Oncology
		HPV16+ cervical cancer		1				C-02,C-04	Finalize enrolment Pt 1
							(Q4 2024)
		HPV16+ head and neck cancer		2					Dose level
	VB10.16					C-03		recommendation
									(H2 2024)
Off-the-shelf		HPV16+ locally advanced		2
						C-05	Protocol in development
		cervical cancer
	Regeneron	Undisclosed		3					Selection of lead
	programs							candidate
	NYK011	Colorectal: pre-cancerous							Update
	polyps to cancer							(H2 2024)
		Melanoma, lung, bladder, renal,		4
Individua-		head and neck cancer; locally						N-01
	advanced and metastatic tumors
lized	VB10.NEO
		Incurable locally advanced and		4			N-02
		metastatic tumors
Infectious Disease			3
Regeneron programs	Undisclosed
Autoimmune
Internal		Undisclosed							Update
							(H1 2024)

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

4

Strong rationale for moving into Immune Tolerance

Autoimmune disease therapy relies on broadly immunosuppressive therapies which leaves a great unmet medical need in a growing market

Inverse vaccines present a new promising avenue with potential for long- lasting efficacy and limited side effects

The field is gaining traction and partnership interest from major players, yet to see first regulatory approval

	Nykode's proprietary APC
Nykode's unique approach leveraging APC-targeting technology offers a differentiated
	targeting technology
	solution that could become a first- or best-in-class therapypresents.	a differentiated
	approach able to become
Nykode Therapeutics |	the first- or best-in-class

Modular design with multiple targeting and 4th modules able to ensure antigen-specific immune tolerance

+/-

Cytokine/

immune modulator

Module 1: Multiple targeting units for receptors on tolerizing APCs identified including natural ligands and other targeting molecules

Module 3: Auto-antigens or allergens known to elicit unwanted immune responses identified

Module 4: Cytokines or modulators playing key roles in mediating anti-inflammatory immune responses

• Numerous exploratory vaccines built on above modules and evaluated experimentally
• Several patent applications covering these concepts filed

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs

MECHANISM OF ACTION - TOLERANCE INDUCTION (INVERSE VACCINATION)

Cells

transfected with

DNA plasmid

vaccine

Tol

APC

Effector

B cell

CD4+

Treg

CD4+

Treg

Tol

APC

Effector	Effector
T cell	T cell

1 Cells encode and secrete Tol APC-targeted Vaccibody proteins together with immunosuppressive molecules/modulators to enhance tolerogenic APC function.

2 The Tol APCs present vaccine antigens in a tolerogenic milieu supported by the vaccine co-encoded suppressive molecules, and prime regulatory T cell (Treg) activation and expansion.

3	The Tregs inhibit or delete disease-
specific effector T cells and inhibit

effector B cells

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

APC targeting is required for effective disease protection

EAE MODEL

Tol.

APC

		TV004	30 µg
	5	TV042
	PBS
score	4
3
EAE	2
1
	0
	6	8	10 12 14 16 18 20 22 24 26 28

			3 µg
	5			5
score	4		score	4
3		3
EAE	2		EAE	2
1		1
	0			0
	6	8	10 12 14 16 18 20 22 24 26 28

		0.3 µg
6	8	10 12 14 16 18 20 22 24 26 28

MOG MOG

(27-63)(27-63)

Days post EAE induction

Days post EAE induction

Days post EAE induction

TV004 TV042

Daily clinical scores

day -7 day -3day 0

day 28

AUC (5-28)

110

90

70

50

30

✱✱✱

✱

✱✱

AUC (5-28)

110

90

70

50

30

✱✱

✱

	110
(5-28)	90
70
50
AUC
30
	10

i.v.

EAE Termination induction

10

10

PBS

TV042

TV004

Pertussis toxin

Mann-Whitney test,

*p<0.05, **p<0.001, ***p<0.0001

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

8

Vaccibody delivers Ag-specific suppression of EAE

EAE MODEL - OVA CONTROL

TV004 TV043

MOGOVA

(27-63)(323-339)

Daily clinical scores

day -7 day -3day 0

day 28

	5
score	4
3	TV004
EAE	2	TV043
	PBS
	1

i.v.

EAE Termination induction

0
6	8	10 12 14 16 18 20 22 24 26 28

Pertussis toxin

Days post EAE induction

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

9

Vaccibody vaccine prevents EAE disease in an early therapeutic setting

				EAE MODEL - EARLY THERAPEUTIC DELIVERY
	TV004
			5		TV004		100	✱✱✱
			4
		scoreEAE		PBS	28)-(5AUC	80
	MOG
	3
	(27-63)					60
	Daily clinical scores (5-28)		2				40
	day 28		1				20
	Termination		0				0
EAE		0	2	4 6 8 10 12 14 16 18 20 22 24 26 28		PBS	TV004
i.v.
induction				Days post EAE induction		Mann-Whitney test, ***p<0.0001
Pertussis toxin

Nykode Therapeutics | ABGSC Seminar 2024 | Non-Confidential

10